bumetanide has been researched along with Osteoporosis, Postmenopausal in 1 studies
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rejnmark, L | 1 |
| Vestergaard, P | 1 |
| Heickendorff, L | 1 |
| Andreasen, F | 1 |
| Mosekilde, L | 1 |
1 trial available for bumetanide and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide.
Topics: Aged; Bone Density; Bone Remodeling; Bumetanide; Calcium; Diuretics; Female; Fractures, Bone; Humans | 2006 |